Grifols (NASDAQ:GRFS) Shares Gap Up – Time to Buy?

Grifols, S.A. (NASDAQ:GRFS) gapped up before the market opened on Friday . The stock had previously closed at $6.52, but opened at $6.81. Grifols shares last traded at $6.79, with a volume of 66,413 shares traded.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley assumed coverage on Grifols in a report on Wednesday, February 12th. They issued an “overweight” rating for the company.

Grifols Stock Up 3.7 %

The stock has a market cap of $4.65 billion, a P/E ratio of 5.78 and a beta of 0.41. The company’s fifty day moving average price is $7.49 and its 200-day moving average price is $7.88. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Institutional Trading of Grifols

Large investors have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Grifols by 20.3% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 266,005 shares of the biotechnology company’s stock worth $1,891,000 after buying an additional 44,818 shares during the period. NBC Securities Inc. raised its holdings in shares of Grifols by 112,543.1% in the 1st quarter. NBC Securities Inc. now owns 57,448 shares of the biotechnology company’s stock valued at $408,000 after purchasing an additional 57,397 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Grifols by 426.1% in the 1st quarter. GAMMA Investing LLC now owns 26,087 shares of the biotechnology company’s stock worth $1,850,000 after purchasing an additional 21,128 shares during the period. Versant Capital Management Inc bought a new position in shares of Grifols during the first quarter valued at approximately $28,000. Finally, Principal Street Partners LLC purchased a new position in Grifols during the fourth quarter valued at approximately $84,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.